Biomerica (BMRA) Competitors $3.14 +0.03 (+0.96%) As of 01:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BMRA vs. SNYR, MDCX, AKTX, MAAQ, MURA, CLNN, ITRM, GBIO, ESLA, and KZRShould you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include Synergy CHC (SNYR), Medicus Pharma (MDCX), Akari Therapeutics (AKTX), Mana Capital Acquisition (MAAQ), Mural Oncology (MURA), Clene (CLNN), Iterum Therapeutics (ITRM), Generation Bio (GBIO), Estrella Immunopharma (ESLA), and Kezar Life Sciences (KZR). These companies are all part of the "pharmaceutical products" industry. Biomerica vs. Its Competitors Synergy CHC Medicus Pharma Akari Therapeutics Mana Capital Acquisition Mural Oncology Clene Iterum Therapeutics Generation Bio Estrella Immunopharma Kezar Life Sciences Biomerica (NASDAQ:BMRA) and Synergy CHC (NASDAQ:SNYR) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings. Does the media prefer BMRA or SNYR? In the previous week, Synergy CHC had 1 more articles in the media than Biomerica. MarketBeat recorded 1 mentions for Synergy CHC and 0 mentions for Biomerica. Synergy CHC's average media sentiment score of 0.63 beat Biomerica's score of 0.00 indicating that Synergy CHC is being referred to more favorably in the news media. Company Overall Sentiment Biomerica Neutral Synergy CHC Positive Which has preferable valuation and earnings, BMRA or SNYR? Synergy CHC has higher revenue and earnings than Biomerica. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomerica$5.41M1.48-$5.98M-$2.32-1.35Synergy CHC$34.83M0.92$2.12MN/AN/A Do institutionals and insiders have more ownership in BMRA or SNYR? 22.3% of Biomerica shares are held by institutional investors. 15.0% of Biomerica shares are held by insiders. Comparatively, 56.6% of Synergy CHC shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is BMRA or SNYR more profitable? Synergy CHC has a net margin of 0.00% compared to Biomerica's net margin of -85.42%. Synergy CHC's return on equity of -8.48% beat Biomerica's return on equity.Company Net Margins Return on Equity Return on Assets Biomerica-85.42% -85.90% -61.06% Synergy CHC N/A -8.48%12.75% Do analysts prefer BMRA or SNYR? Synergy CHC has a consensus target price of $10.00, indicating a potential upside of 187.36%. Given Synergy CHC's stronger consensus rating and higher probable upside, analysts plainly believe Synergy CHC is more favorable than Biomerica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomerica 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Synergy CHC 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 SummarySynergy CHC beats Biomerica on 12 of the 14 factors compared between the two stocks. Get Biomerica News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMRA vs. The Competition Export to ExcelMetricBiomericaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.01M$2.43B$5.46B$9.66BDividend YieldN/A1.78%3.99%4.14%P/E Ratio-1.3520.1130.0324.98Price / Sales1.48426.69375.7076.70Price / CashN/A165.0335.9458.58Price / Book1.004.168.155.67Net Income-$5.98M$31.61M$3.25B$265.39M7 Day Performance-0.32%0.57%1.13%2.51%1 Month Performance-3.98%2.65%2.83%1.85%1 Year Performance32.96%4.60%28.39%24.09% Biomerica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMRABiomerica0.4617 of 5 stars$3.14+1.0%N/A+29.7%$8.01M$5.41M-1.3560Positive NewsSNYRSynergy CHC3.9948 of 5 stars$3.53+0.6%$10.00+183.3%N/A$32.44M$34.83M0.0040Gap DownMDCXMedicus Pharma2.3314 of 5 stars$2.37-0.4%$23.50+891.6%N/A$32.16MN/A-2.04N/ANews CoverageAKTXAkari Therapeutics3.272 of 5 stars$1.00-3.4%$5.00+402.5%-72.1%$32.02MN/A0.009MAAQMana Capital AcquisitionN/A$3.88-6.3%N/A+864.0%$31.53MN/A0.001MURAMural Oncology2.7101 of 5 stars$1.81-2.2%$12.00+563.0%-48.8%$31.26MN/A-0.24119Earnings ReportUpcoming EarningsGap DownCLNNClene3.0493 of 5 stars$3.70-1.1%$40.00+981.1%-18.4%$30.60M$340K-0.92100ITRMIterum Therapeutics1.5806 of 5 stars$0.74+3.1%$9.00+1,122.8%-36.9%$30.50MN/A-0.7310Earnings ReportShort Interest ↑Gap UpHigh Trading VolumeGBIOGeneration Bio3.5621 of 5 stars$4.52-1.3%$80.00+1,669.9%-81.3%$30.28M$19.89M-0.42150ESLAEstrella Immunopharma2.3707 of 5 stars$0.84+0.8%$16.00+1,816.2%-38.9%$30.20MN/A-3.21N/AKZRKezar Life Sciences3.6765 of 5 stars$4.12+0.5%$39.50+858.7%-29.8%$30.12M$7M-0.3860Negative NewsUpcoming EarningsShort Interest ↑High Trading Volume Related Companies and Tools Related Companies Synergy CHC Alternatives Medicus Pharma Alternatives Akari Therapeutics Alternatives Mana Capital Acquisition Alternatives Mural Oncology Alternatives Clene Alternatives Iterum Therapeutics Alternatives Generation Bio Alternatives Estrella Immunopharma Alternatives Kezar Life Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMRA) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomerica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomerica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
